MA31283B1 - Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse - Google Patents

Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse

Info

Publication number
MA31283B1
MA31283B1 MA32057A MA32057A MA31283B1 MA 31283 B1 MA31283 B1 MA 31283B1 MA 32057 A MA32057 A MA 32057A MA 32057 A MA32057 A MA 32057A MA 31283 B1 MA31283 B1 MA 31283B1
Authority
MA
Morocco
Prior art keywords
treatment
hyperliferative
dihydroimidazo
disorders
substituted
Prior art date
Application number
MA32057A
Other languages
Arabic (ar)
English (en)
Inventor
Martin Hentemann
Jill Wood
William Scott
Martin Michels
Ann-Marie Campbell
Ann-Marie Bullion
R Bruce Rowley
Aniko Redman
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39492563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31283(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MA31283B1 publication Critical patent/MA31283B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/54—1,3-Diazines; Hydrogenated 1,3-diazines
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)

Abstract

L'invention concerne des composés nouveaux de 2,3-dihydroimidazo[1,2-c]quinazoline, des compositions pharmaceutiques contenant de tels composés et l'utilisation de ces composés ou compositions pour l'inhibition de la phosphotidylinositol-3-kinase (pi3k) et le traitement de maladies associées à l'activité de la phosphotidylinositol-3-kinase (pi3k), en particulier pour le traitement de troubles hyperlifératifs et/ou de l'angiogenèse, en tant qu'agent unique ou en combinaison avec d'autres ingrédients actifs.
MA32057A 2006-12-05 2009-06-29 Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse MA31283B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87309006P 2006-12-05 2006-12-05
PCT/US2007/024985 WO2008070150A1 (fr) 2006-12-05 2007-12-05 Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse

Publications (1)

Publication Number Publication Date
MA31283B1 true MA31283B1 (fr) 2010-04-01

Family

ID=39492563

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32057A MA31283B1 (fr) 2006-12-05 2009-06-29 Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse

Country Status (41)

Country Link
US (3) USRE46856E1 (fr)
EP (1) EP2096919B1 (fr)
JP (1) JP5326092B2 (fr)
KR (1) KR101501785B1 (fr)
CN (4) CN101631464B (fr)
AR (1) AR064106A1 (fr)
AU (1) AU2007328008B2 (fr)
BR (1) BRPI0720178B8 (fr)
CA (1) CA2671614C (fr)
CL (1) CL2007003508A1 (fr)
CO (1) CO6220908A2 (fr)
CR (1) CR10838A (fr)
CU (1) CU23796B7 (fr)
DK (1) DK2096919T3 (fr)
DO (1) DOP2009000135A (fr)
EA (1) EA018839B1 (fr)
EC (1) ECSP099387A (fr)
ES (1) ES2572189T3 (fr)
GT (1) GT200900154A (fr)
HN (1) HN2009001131A (fr)
HU (1) HUE028773T2 (fr)
IL (1) IL198273A (fr)
JO (1) JO3147B1 (fr)
MA (1) MA31283B1 (fr)
MX (1) MX2009006001A (fr)
MY (1) MY157944A (fr)
NO (1) NO342348B1 (fr)
NZ (1) NZ577342A (fr)
PA (1) PA8759601A1 (fr)
PE (1) PE20081444A1 (fr)
PL (1) PL2096919T3 (fr)
RS (1) RS56045B1 (fr)
SG (1) SG177170A1 (fr)
SI (1) SI2096919T1 (fr)
SV (1) SV2009003288A (fr)
TN (1) TN2009000137A1 (fr)
TW (1) TWI406662B (fr)
UA (1) UA96965C2 (fr)
UY (1) UY30761A1 (fr)
WO (1) WO2008070150A1 (fr)
ZA (1) ZA200904691B (fr)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2244721A4 (fr) * 2008-01-14 2017-01-18 Bayer Intellectual Property GmbH Dérivés de 2,3-dihydroimidazo ý1,2-c¨quinazoline à substitution sulfone utilisés pour traiter des troubles hyperproliférants et des maladies associées à l'angiogénèse
EP2168583A1 (fr) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées pour le traitement du myélome
EP2168582A1 (fr) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Combinaisons de 2,3-dihydroimidazo[1,2-c]quinazolines substituées
JP5591809B2 (ja) * 2008-09-30 2014-09-17 ファイザー・インク イミダゾ［１，５］ナフチリジン化合物、その医薬への使用、および組成物
EP2184276A1 (fr) 2008-11-07 2010-05-12 Universite Paul Cezanne Aix-Marseille Iii Procédé de préparation de nouvelles 1H-benzo(d) imidazol-2(3h)-ones substituées, de nouveaux intermédiaires et leur utilisation en tant qu'inhibiteurs de bace 1
JP5569397B2 (ja) * 2009-01-16 2014-08-13 ダイソー株式会社 ２−ヒドロキシメチルモルホリン塩の製造方法
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
CA2796253A1 (fr) 2010-04-16 2011-10-20 Bayer Intellectual Property Gmbh Combinaisons contenant une 2,3-dihydroimidazo[1,2-c]quinazoline substituee
EP2582709B1 (fr) 2010-06-18 2018-01-24 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2012030165A2 (fr) 2010-08-31 2012-03-08 서울대학교산학협력단 Utilisation de la reprogrammation fœtale d'un agoniste des ppar δ
US9730943B2 (en) * 2010-11-11 2017-08-15 Bayer Intellectual Property Gmbh Alkoxy-substituted 2,3-dihydroimidazo[1,2-C]quinazolines
CN103370320B (zh) * 2010-11-11 2016-04-27 拜耳知识产权有限责任公司 芳基氨基醇取代的2,3-二氢咪唑并[1,2-c]喹啉
UA113280C2 (xx) * 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
JO3733B1 (ar) * 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP2508525A1 (fr) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Sels de 2,3-dihydroimidazo[1,2-C]quinazoline substitutés
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2567959B1 (fr) 2011-09-12 2014-04-16 Sanofi Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
BR112014031421A2 (pt) * 2012-06-15 2017-06-27 Brigham & Womens Hospital Inc composições para tratamento de câncer e métodos para produção das mesmas
US20150258127A1 (en) 2012-10-31 2015-09-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
US9694071B2 (en) * 2012-11-02 2017-07-04 Tg Therapeutics, Inc. Combination of anti-CD20 antibody and PI3 kinase selective inhibitor
CN103214489B (zh) * 2013-02-25 2016-10-26 中国人民解放军第二军医大学 一类具有抗肿瘤活性的多靶点激酶抑制剂及其制备方法
EA031493B9 (ru) 2013-04-08 2019-12-18 Байер Фарма Акциенгезельшафт Комбинация и фармацевтическая композиция для лечения или профилактики неходжкинской лимфомы (нхл)
CN104557955B (zh) * 2013-10-23 2017-05-03 上海汇伦生命科技有限公司 作为PI3K/mTOR抑制剂的三环类化合物，其制备方法和用途
US20150148345A1 (en) * 2013-11-26 2015-05-28 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
US10124007B2 (en) 2013-12-03 2018-11-13 Bayer Pharma Aktiengesellschaft Combination of PI3K-inhibitors
CN105934256B (zh) * 2013-12-03 2019-12-27 拜耳制药股份公司 Pi3k-抑制剂的组合产品
TWI533869B (zh) 2014-03-11 2016-05-21 國立中央大學 蒽醌［２，１－ｃ］［１，２，５］噻二唑－６，１１－二酮化合物緩解疼痛的應用
TWI533871B (zh) 2014-03-11 2016-05-21 國立中央大學 萘并［２，３－ｆ］喹喔啉－７，１２－二酮化合物緩解疼痛的應用
FR3018813B1 (fr) * 2014-03-18 2016-04-15 Maco Pharma Sa Procede de synthese d'un derive de psoralene
WO2016059220A1 (fr) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Agents d'activation du tcr à utiliser dans le traitement de la lla-t
EP3018127A1 (fr) * 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthèse de copanlisib et son sel de dichlorhydrate
EP3018131A1 (fr) * 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthèse de copanlisib et son sel de dichlorhydrate
CN107683138A (zh) * 2015-03-09 2018-02-09 拜耳制药股份公司 取代的2,3‑二氢咪唑并[1,2‑c]喹唑啉类化合物的用途
MX2017011635A (es) * 2015-03-09 2018-02-09 Bayer Pharma AG Combinaciones que contienen 2,3-dihidroimidazo[1,2-c]quinazolina sustituida.
FR3033499A1 (fr) * 2015-03-11 2016-09-16 Centre Leon-Berard Composition pour le traitement des tumeurs neuroendocrines pancreatiques
EP4585597A1 (fr) * 2015-07-02 2025-07-16 F. Hoffmann-La Roche AG Composés de benzoxazepine oxazolidinone et procédés d'utilisation
CN105130998B (zh) * 2015-09-25 2017-07-28 苏州立新制药有限公司 库潘尼西的制备方法
CN105130997B (zh) * 2015-09-25 2017-12-05 苏州明锐医药科技有限公司 一种库潘尼西的制备方法
EP3426657B1 (fr) * 2016-03-08 2022-07-13 Bayer Pharma Aktiengesellschaft 2-amino-n-[7-méthoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides
EP3219329A1 (fr) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinaisons de copanlisib
CN109843378B (zh) * 2016-05-26 2022-06-10 匹兹堡大学联邦高等教育系统 用于治疗肺血管疾病的组合物和方法
WO2017211248A1 (fr) * 2016-06-08 2017-12-14 深圳市塔吉瑞生物医药有限公司 Composé d'imidazoquinazoline substitué et composition pharmaceutique correspondante
CN109729716B (zh) 2016-09-23 2022-03-15 拜耳制药股份公司 Pi3k-抑制剂的组合产品
CN106177918A (zh) * 2016-09-30 2016-12-07 广州赛莱拉干细胞科技股份有限公司 一种间充质干细胞注射液及其制备方法和应用
CA3045041A1 (fr) 2016-12-14 2018-06-21 Tarveda Therapeutics, Inc. Conjugues ciblant hsp90 et formulations de ces derniers
US11684672B2 (en) 2017-02-24 2023-06-27 Bayer Pharma Aktiengesellschaft Combinations of copanlisib with anti-PD-1 antibody
WO2018215282A1 (fr) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combinaison d'inhibiteurs de bub1 et de pi3k
CA3068324A1 (fr) 2017-06-28 2019-01-03 Bayer Consumer Care Ag Combinaison d'un inhibiteur de pi3k et d'un antagoniste du recepteur des androgenes
US11253594B2 (en) * 2017-07-07 2022-02-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Drug combinations for protecting against neuronal cell death
CN111542522B (zh) * 2017-08-11 2021-10-15 苏州韬略生物科技有限公司 可用作激酶抑制剂的被取代的吡唑并嘧啶
EP3498266A1 (fr) 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulations de copanlisib
JP2020533292A (ja) 2017-09-08 2020-11-19 バイエル・コンシューマー・ケア・アクチェンゲゼルシャフトＢａｙｅｒ Ｃｏｎｓｕｍｅｒ Ｃａｒｅ ＡＧ コパンリシブの製剤
WO2019105734A1 (fr) 2017-11-28 2019-06-06 Bayer Consumer Care Ag Combinaisons de copanlisib
WO2019105835A1 (fr) 2017-11-29 2019-06-06 Bayer Consumer Care Ag Combinaisons de copanlisib et d'anetumab ravtansine
WO2019197269A1 (fr) 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinaisons de copanlisib et de dérivés de triazolone ainsi que leur utilisation dans le traitement du cancer
CN108383849B (zh) * 2018-04-26 2020-11-06 浙江大学 咪唑并喹唑啉衍生物及其在抗肿瘤抗炎中的应用
CN108841318A (zh) * 2018-07-12 2018-11-20 中国科学院海洋研究所 一种自修复壳聚糖水凝胶防腐涂料及其合成方法
EP3843743A1 (fr) 2018-08-28 2021-07-07 Bayer AS Combinaison d'inhibiteurs de pi3k et de conjugués de thorium ciblés
US20210369724A1 (en) 2018-10-16 2021-12-02 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
CN109516961B (zh) * 2018-12-25 2021-01-01 浙江大学 氨基喹唑啉酮和氨基异喹啉酮衍生物及其应用
WO2020164997A1 (fr) 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combinaison d'inhibiteurs de la pi3k
KR102890609B1 (ko) * 2021-11-30 2025-11-25 광주과학기술원 Pip4k2c 억제제를 유효성분으로 포함하는 암 치료용 조성물
WO2023139125A1 (fr) 2022-01-18 2023-07-27 Synthon B.V. Procédé amélioré de préparation de copanlisib
WO2023218032A1 (fr) 2022-05-13 2023-11-16 Synthon B.V. Formes solides de sels de copanlisib

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644354A (en) 1968-09-16 1972-02-22 Sandoz Ag 5-substituted-2 3-dihydroimidazo(1 2-c)quinazolines
US4146718A (en) 1978-04-10 1979-03-27 Bristol-Myers Company Alkyl 5,6-dichloro-3,4-dihydro-2(1h)-iminoquinazoline-3-acetate hydrohalides
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
JP3729343B2 (ja) * 2000-04-27 2005-12-21 アステラス製薬株式会社 縮合ヘテロアリール誘導体
PA8578001A1 (es) * 2002-08-07 2004-05-07 Warner Lambert Co Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
ES2312843T3 (es) * 2002-09-30 2009-03-01 Bayer Healthcare Ag Derivados de azolpirimidina condensados.
WO2004112699A2 (fr) * 2003-06-12 2004-12-29 Merck & Co., Inc. Inhibiteurs de kinesine mitotique
AT412873B (de) 2004-02-20 2005-08-25 Aop Orphan Pharmaceuticals Ag Verfahren zur herstellung von anagrelid hydrochlorid
WO2007143483A2 (fr) 2006-06-01 2007-12-13 Smithkline Beecham Corporation Procédé de traitement du cancer
WO2008002039A1 (fr) 2006-06-28 2008-01-03 Hanmi Pharm. Co., Ltd. Dérivés de quinazoline destinés à inhiber le développement de cellules cancéreuses
EP2508525A1 (fr) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Sels de 2,3-dihydroimidazo[1,2-C]quinazoline substitutés

Also Published As

Publication number Publication date
JP5326092B2 (ja) 2013-10-30
CN105254634A (zh) 2016-01-20
NZ577342A (en) 2012-01-12
PE20081444A1 (es) 2008-11-29
ECSP099387A (es) 2009-11-30
EA200900733A1 (ru) 2009-12-30
BRPI0720178A2 (pt) 2013-12-24
GT200900154A (es) 2012-01-17
NO20092529L (no) 2009-08-27
DK2096919T3 (en) 2016-05-17
TN2009000137A1 (en) 2010-10-18
TWI406662B (zh) 2013-09-01
CA2671614A1 (fr) 2008-06-12
MX2009006001A (es) 2009-06-16
TW200840582A (en) 2008-10-16
MY157944A (en) 2016-08-30
US8466283B2 (en) 2013-06-18
AU2007328008B2 (en) 2014-03-13
CN108774232B (zh) 2022-08-09
CN105254634B (zh) 2022-05-27
CN115724847A (zh) 2023-03-03
BRPI0720178B8 (pt) 2021-05-25
PA8759601A1 (es) 2009-02-09
CR10838A (es) 2009-11-05
PL2096919T3 (pl) 2016-08-31
ZA200904691B (en) 2010-09-29
HK1217953A1 (zh) 2017-01-27
CU23796B7 (es) 2012-03-15
CL2007003508A1 (es) 2008-07-04
AU2007328008A1 (en) 2008-06-12
WO2008070150A1 (fr) 2008-06-12
USRE46856E1 (en) 2018-05-22
US20110083984A1 (en) 2011-04-14
EA018839B1 (ru) 2013-11-29
SV2009003288A (es) 2009-10-02
SG177170A1 (en) 2012-01-30
ES2572189T3 (es) 2016-05-30
CN108774232A (zh) 2018-11-09
AR064106A1 (es) 2009-03-11
UY30761A1 (es) 2008-07-03
EP2096919A4 (fr) 2010-11-17
KR20090096440A (ko) 2009-09-10
JO3147B1 (ar) 2017-09-20
CU20090103A7 (es) 2011-12-28
DOP2009000135A (es) 2009-06-30
UA96965C2 (ru) 2011-12-26
KR101501785B1 (ko) 2015-03-11
NO342348B1 (no) 2018-05-07
BRPI0720178B1 (pt) 2019-04-09
JP2010511718A (ja) 2010-04-15
CN101631464B (zh) 2022-12-06
CA2671614C (fr) 2016-01-26
SI2096919T1 (sl) 2016-06-30
CO6220908A2 (es) 2010-11-19
HN2009001131A (es) 2012-02-06
CN101631464A (zh) 2010-01-20
EP2096919B1 (fr) 2016-03-02
EP2096919A1 (fr) 2009-09-09
IL198273A0 (en) 2009-12-24
RS56045B1 (sr) 2017-09-29
IL198273A (en) 2015-07-30
HUE028773T2 (en) 2017-01-30
US20130261113A1 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
MA31283B1 (fr) Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
TNSN08445A1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
MA59379B1 (fr) Aminothiazoles substitués en tant qu'inhibiteurs de dgkzeta pour l'activation immunitaire
MA33239B1 (fr) 3h-imidazo [4,5-c] pyridine-6-carboxamides en tant qu'anti-inflammatoires
MA29568B1 (fr) Composes d'azaindazole et methodes d'utilisation desdits composes
MA29411B1 (fr) 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
MA33726B1 (fr) Composes de dioxyde d'iminothiadiazine comme inhibiteurs de bace, compositions et leur utlisation
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
TN2010000230A1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA27428A1 (fr) Derives de pyrimidine et leur utilisation en tant que modulateurs cb2
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MA28437B1 (fr) Composes et leurs procedes d'utilisation
MA29213B1 (fr) Quinolones a substitution macrolones - amino
TN2009000138A1 (fr) Biaryl-ether-urees
MA47447B1 (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
MA33920B1 (fr) Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide
MA30999B1 (fr) Composés.
MA27997A1 (fr) Composes et compositions inhibiteurs de l'activite du recepteur tyrosine kinase
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA35422B1 (fr) Imidazopyridazines amino-substituees
MA32009B1 (fr) Nouveaux derives de pyrazolo [3,4-d]pyrimidine en tant qu'agents anticancereux